Movement Disorders

Data from a PMD Alliance survey of more than 700 individuals with PD or their care partners showed significant associations between decreased social support and exasperation of nonmotor and cognitive symptoms of PD.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement and related disorders.

A survey of more than 4000 individuals with PD and their caregivers suggests that almost 90% would be willing to use subcutaneous injectable therapies to control their disease, contrasting the current anecdotal belief of “needle phobia” in this population.

The study, expected to be completed in 2024, will look specifically at vocal abnormalities related to the early stages of Parkinson disease progression.

The semi-retired neurologist and consultant with the PMD Alliance discussed the importance of the patient care team and having multiple specialists and disciplines included in that process. [WATCH TIME: 2 minutes]

In a presentation at the 2022 ATMRD Congress, Jill Farmer, DO, MPH, outlined several novel options for the treatment of OFF episodes in Parkinson disease, and stressed the need for individualized approaches to maximize patient quality of life.

In a first, but indirect, comparison of the 3 available formulations of amantadine for the treatment of Parkinson disease, only the delayed-release/extended-release formulation (Gocovri) resulted in improvements in both in OFF time and dyskinesia.

The semi-retired neurologist and consultant with the PMD Alliance shared her perspective on the progress that has been made in therapeutics for the treatment of movement disorders, and the role of social prescribing for these patients. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 17, 2022.

The investigators noted that the data on tolerability and efficacy support that treatment with opicapone among older adults with PD requires no age-related dose adjustments.

Robert A. Hauser, MD, MBA, and Laxman Bahroo, DO, review unmet needs in managing OFF episodes for patients with Parkinson Disease.

Rajesh Pahwa, MD, provides insight on initiating treatment after the manifestation of OFF episodes and reviews current treatment options for Parkinson disease.

Drs Robert A. Hauser, Rajesh Pahwa, and Laxman Bahroo discuss factors to consider when approaching treatment selection for managing OFF episodes in Parkinson Disease.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Headache Society.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 10, 2022.

Experts in movement disorders share the importance of multidisciplinary team collaboration for the management of OFF episodes and shared-decision making for treating Parkinson disease.

Robert A. Hauser, MD, MBA, and Rajesh Pahwa, MD, comment on therapeutic obstacles in treating OFF episodes and how to optimize the management of patients with Parkinson disease.

Rajesh Pahwa, MD, leads a discussion on approaching conversations about ON and OFF episodes in Parkinson disease throughout a patient’s treatment journey.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 3, 2022.

Rajesh Pahwa, MD; Robert A. Hauser, MD, MBA; and Laxman Bahroo, DO, provide insight on the challenges with motor and nonmotor symptoms of OFF episodes for patients with Parkinson Disease.

Drs Rajesh Pahwa, Robert A. Hauser, and Laxman Bahroo assess the awareness of OFF episodes in patients with Parkinson Disease and comment on improving education and awareness among non-neurology clinicians and other health care providers.

Rajesh Pahwa, MD; Laxman Bahroo, DO; and Robert A. Hauser, MD, MBA, examine the impact of OFF episodes on patients and their families’ quality of life and discuss goals of therapy for Parkinson Disease.

The founder and chief medical officer of Omniscient Neurotechnology discussed how the use of machine learning and big data will be critical in revolutionizing our understanding of the brain and mental illnesses.

The founder and chief medical officer of Omniscient Neurotechnology commented on the areas of need with understanding the brain map and treating conditions with multiple pathway crossover. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is World MS Day.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 27, 2022.